A formulation comprising an ingestible carrier and an isolated strain of Bifidobacterium longum.

In various implementations, one or more compositions may be provided to improve or maintain oral and/or intestinal health. For example, a dental powder, toothpaste, mouthwash, and/or probiotic composition may be administered to improve or maintain oral and/or intestinal health. In some implementations, an intestinal health kit that includes cleanse compositions, renewal compositions, and/or digestion aids (e.g., enzymes) may be administered to improve or maintain intestinal health and/or fitness.

The inventions described herein relate generally to digestive healthcare, and more particularly, to the feeding of mammals, particularly human infants, who are making a transition from a microbiome with lower diversity to a microbiome with higher diversity. These inventions relate to certain foods comprising a fermentable nutritional component and a probiotic component, where the probiotic component is selected, based on genetic and/or metabolic criteria, to specifically metabolize any Free Sugar Monomers (FSMs) and Free Amino Acids (FAAs) or peptides that accumulate as a result of the fermentable nutritional component in the lower intestine, where they otherwise might be left in the environment to be fermented and metabolized by less adapted/opportunistic bacteria, creating blooms of deleterious intestinal bacteria and shifting the microbiome to a potentially dysbiotic state. The present inventions provide combinations of foods and probiotic bacteria that can protect the mammalian gut from blooms of pathogenic bacteria under the circumstances where the mammalian gut is starting out with a low microbial diversity, such as in weaning infants, or individuals who are post-antibiotic treatment and/or post-chemotherapeutic treatment and transitioning to a higher diversity adapted/stable microbiome.

A composition comprising combination of salt, sugar and lactic acid bacteria as an active ingredient to treat vaginosis. The composition showed potent antibacterial activity through various experiments, for example, (1) the indirect inhibitory activity test from the growth of vaginosis causing bacteria by determining the change of pH and lactic acid level; (2) the direct inhibitory activity test from the growth of vaginosis causing bacteria by determining the susceptibility of test sample; (3) brief clinical tests, and finally confirmed that the combination showed potent antibacterial activity in the test. Accordingly, the combination may be useful to alleviate and treat vaginosis in the form of a pharmaceutical composition, health functional food, food additive, topical composition, and detergent composition.

Processes for producing a nutritional supplement that contains sulforaphane, and supplements formed thereby. Such a process includes combining a cruciferous vegetable, for example, broccoli sprouts, with strains of Lactobacillus, Streptococcus and Bifidobacterium to form a mixture, causing the mixture to undergo lactic acid fermentation, transform a glucosinolate within the cruciferous vegetable to sulforaphane, and yield a fermented mixture that contains sulforaphane, and then producing from the fermented mixture a supplement that can be ingested by an individual.

The present disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria are grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder.

The strain Lactobacillus casei AH077 (NCIMB12019) produces a polysaccharide and increases energy excretion. The strain acts to block fat absorption and is used in the prevention or treatment of obesity and obesity-related metabolic syndrome.

The present disclosure relates to novel sialidase enzymes having a preference for cleaving N-glycolylneuraminic acid (Neu5Gc) from glycoconjugates over cleaving N-acetyineuraminic acid (Neu5Ac). The present disclosure further provides the polypeptide of such novel sialidase and its catalytic pockets; the recombinant host cells expressing the same, as well as the enzymatic, pharmaceutical, and consumable compositions comprising such novel sialidases. Probiotic compositions comprising a bacterium that expresses the sialidase having a preference for Neu5Gc over Neu5Ac, and methods for removing Neu5Gc from consumable products are also provided. Also disclosed are methods for treating or preventing various diseases, disorders, and inflammatory conditions in a subject using the novel sialidases.

Probiotic Bifidobacterium strain AH1714 is significantly immunomodulatory following oral consumption. The strain is useful as an immunomodulatory biotherapeutic agent.

This invention relates to a preparation comprising a probiotic bacterial strain and a prebiotic mixture comprising 5-70 wt % of at least one N-acetylated oligosaccharide selected from the group consisting of Ga1NAc1-3Ga11-4G1c, Ga11-6Ga1Nac1-3Ga11-4G1c and combinations thereof, 20-95 wt % of at least one neutral oligosaccharide selected from the group consisting of Gal1-6Gal, Gal1-6Gal1-4Glc, Gal1-6Gal1-6Glc, Gal1-3Gal1-3Glc, Gal1-3Gal1-4Glc, Gal1-6Gal1-6Gal1-4Glc, Gal1-6Gal1-3Gal1-4Glc, Gal1-3Gal1-6Gal1-4Glc, Gal1-3Gal1-3Gal1-4Glc and combinations thereof and 2-50 wt % of at least one sialylated oligosaccharide selected from the group consisting of NeuAc2-3Gal1-4Glc, NeuAc2-6Ga11-4G1c and combinations thereof. The invention extends to food products comprising said preparation and to the use of the preparation in the prevention and treatment of infections.